GlassScriptPhysician profile
Rehan Shafique
NPI 1851510143
$6,757.78
in general payments reported to CMS, 2019-2025
30 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $152 · 2021: $718 · 2022: $1,699 · 2023: $884 · 2024: $1,298 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,060 · Education: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,059.91 |
| Education | $337.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $741.81 | 2019-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $728.94 | 2019-2025 | Jynarque, Voyxact |
| Aurinia Pharma U.S., INC. | $713.38 | 2021-2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $602.09 | 2019-2024 | Velphoro |
| Travere Therapeutics, INC. | $468.30 | 2023-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $365.61 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $342.00 | 2021-2025 | Acthar |
| Ardelyx, INC. | $301.96 | 2023-2025 | Ibsrela |
| Vifor Pharma, INC. | $259.55 | 2019-2024 | Veltassa |
| Amgen INC. | $254.30 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Novartis Pharmaceuticals Corporation | $252.92 | 2024-2025 | |
| Medtronic, INC. | $250.21 | 2022 | |
| Opko Pharmaceuticals, LLC | $240.00 | 2021-2025 | Rayaldee |
| Mallinckrodt Enterprises LLC | $167.44 | 2019 | |
| Lilly USA, LLC | $139.97 | 2022-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $134.67 | 2022 | |
| Glaxosmithkline, LLC. | $131.36 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $118.96 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.25 | 2023-2025 | Jardiance |
| Vantive US Healthcare LLC | $76.83 | 2025 | Renal - Pd |
| Corcept Therapeutics | $62.18 | 2021-2024 | Korlym |
| Sequel Med Tech, LLC | $56.67 | 2025 | Twiist |
| Alexion Pharmaceuticals, INC. | $51.22 | 2019-2022 | |
| Akebia Therapeutics INC | $42.68 | 2020-2024 | Vafseo |
| Calliditas Therapeutics US INC. | $37.60 | 2025 | Tarpeyo |
| Novo Nordisk INC | $36.19 | 2022-2024 | Rybelsus, Ozempic |
| Xeris Pharmaceuticals, INC. | $23.09 | 2024 | Recorlev |
| Sanofi-Aventis U.S. LLC | $19.31 | 2023 | |
| Lifescan, INC. | $17.71 | 2022 | |
| Recor Medical INC | $16.58 | 2025 | Paradise Ultrasound Renal Denervation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rehan Shafique listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.